Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 4 |
| 1.1 List of Tables | 5 | 1 |
| 1.2 List of Figures | 6 | 1 |
| 2 Introduction | 7 | 2 |
| 2.1 GBI Research Report Guidance | 7 | 2 |
| 3 Market Overview | 9 | 7 |
| 3.1 Stem Cell Research An Introduction | 9 | 1 |
| 3.2 Types of Stem Cell Research | 9 | 1 |
| 3.3 Unmet Needs | 10 | 4 |
| 3.4 Applications of Stem Cell Research | 14 | 2 |
| 4 Market Characterization | 16 | 19 |
| 4.1 Stem Cell Market An Introduction | 16 | 1 |
| 4.2 Market Sizing | 16 | 2 |
| 4.3 Therapy cost | 18 | 1 |
| 4.4 Technology Adoption Framework | 19 | 1 |
| 4.5 Types of Business Models | 19 | 2 |
| 4.6 Market Drivers | 21 | 1 |
| 4.6.1 Supporting Political Environment on Embryonic Stem Cell Research will Advance the Stem Cell Industry to Prosper in the United States | 21 | 1 |
| 4.6.2 Limited Availability of Treatments to Treat Certain Disease Conditions Increases Market Opportunity for Stem Cell Research | 22 | 1 |
| Market Barriers &Challenges | 23 | 1 |
| 4.7.1 Stem Cell Research and Development is an expensive process which requires considerable funding to be operational. | 23 | 1 |
| 4.7.2 Availability of Adequate Reimbursements are Unclear and leads to a conundrum | 23 | 1 |
| 4.7.3 Ethical, legal and social issues persists and acts as a challenge | 24 | 1 |
| Identifying, recruiting and retaining the best scientific talents is an intractable process for stem cell research based companies | 25 | 1 |
| 4.8 Stem Cell Research and Development - Market Trends | 25 | 1 |
| 4.8.1 Booming Stem Cell Tourism is a Potential Opportunity for Countries to Attract Investments. | 25 | 1 |
| 4.8.2 ASLAP Analysis of Stem Cell Tourism | 26 | 1 |
| 4.8.2.1 The Present Situation | 26 | 1 |
| 4.8.2.2 Actors | 26 | 1 |
| 4.8.2.3 Process | 26 | 1 |
| 4.8.2.4 Learning | 27 | 1 |
| 4.8.2.5 Actions | 27 | 1 |
| 4.8.2.6 Performance | 27 | 1 |
| 4.8.3 Federal Funding Support Improves the Stem Cell Research Environment | 27 | 1 |
| 4.8.4 Increasing Entry of Pharmaceutical Companies Boosts Stem Cell Research &Development | 28 | 2 |
| 4.8.5 PESTLE Analysis | 30 | 1 |
| 4.8.5.1 Political Environment | 30 | 1 |
| 4.8.5.2 Economic Environment | 30 | 1 |
| 4.8.5.3 Society | 30 | 1 |
| 4.8.5.4 Technology | 30 | 1 |
| 4.8.5.5 Legislation | 30 | 1 |
| Environment | 31 | 1 |
| 4.8.6 SWOT Analysis of Stem Cell Research &Development | 31 | 1 |
| 4.8.6.1 Strengths | 31 | 1 |
| 4.8.6.2 Weakness | 31 | 1 |
| 4.8.6.3 Opportunities | 31 | 1 |
| 4.8.6.4 Threats | 32 | 1 |
| 4.9 Industry Analysis | 33 | 1 |
| 4.9.1.1 Industry Rivalry | 33 | 1 |
| 4.9.1.2 Threat of New Entrant | 33 | 1 |
| 4.9.1.3 Threat of Substitutes | 34 | 1 |
| 4.9.1.4 Supplier Power | 34 | 1 |
| 4.9.1.5 Buyer Power | 34 | 1 |
| Stem Cell Research and Development - Pipeline Analysis | 35 | 5 |
| 5.1 Pipeline by Various Phases | 35 | 1 |
| 5.2 Phase III Pipeline Analysis | 35 | 2 |
| 5.3 Phase II Pipeline Analysis | 37 | 2 |
| 5.4 Preclinical and Phase 1 Pipeline | 39 | 1 |
| Stem Cell Research and Development - Investment Trends | 40 | 7 |
| 6.1 Investor s Perspective on Stem Cell Research | 40 | 1 |
| 6.1.1.1 Status of Research | 41 | 1 |
| 6.1.1.2 Regulatory Position | 41 | 1 |
| 6.1.1.3 Clinical Development | 41 | 1 |
| 6.1.1.4 Commercial Models | 41 | 1 |
| 6.1.1.5 Patent Policy | 42 | 1 |
| 6.2 NIH spending in Stem Cell Research and Development is Increasing and is Supportive | 42 | 1 |
| 6.2.1 NIH Spending by Stem Cell Research Type | 43 | 1 |
| 6.2.2 High Budget Projects Funded by NIH | 44 | 1 |
| 6.3 States Funding on Stem Cell Research in the US is in Reconsideration. | 45 | 1 |
| 6.4 R&D Spending by Stem Cell Research Companies | 46 | 1 |
| 7 Stem Cell Research and Development - Geographical Trends | 47 | 17 |
| 7.1 Stem Cell Companies by Geographic Regions | 47 | 1 |
| 7.2 The United States | 48 | 1 |
| 7.3 United Kingdom | 49 | 1 |
| 7.4 China | 50 | 1 |
| 7.5 Netherlands | 51 | 1 |
| 7.6 Singapore | 52 | 1 |
| 7.7 South Korea | 53 | 1 |
| 7.8 Japan | 54 | 1 |
| 7.9 India | 55 | 1 |
| 7.10 Sweden | 56 | 1 |
| 7.11 Denmark | 57 | 1 |
| 7.12 France | 58 | 1 |
| 7.13 Germany | 59 | 1 |
| 7.14 Israel | 60 | 1 |
| 7.15 Australia | 61 | 1 |
| 7.16 Canada | 62 | 1 |
| 7.17 Czech Republic | 63 | 1 |
| 8 Stem Cell Research and Development - Mergers and Acquisitions | 64 | 1 |
| Stem Cell Research and Development - Competitive Structure | 65 | 2 |
| 9.1 Stem Cell Companies by Therapy Areas | 65 | 1 |
| Stem Cell Companies by Stem Cell Types | 66 | 1 |
| 10 Stem Cell Research and Development - Company Profiles | 67 | 6 |
| 10.1 Aastrom Biosciences | 67 | 1 |
| 10.2 Osiris Therapeutics | 67 | 1 |
| 10.3 Bioheart | 68 | 1 |
| 10.4 Aldagen | 68 | 1 |
| 10.5 Mesoblast | 69 | 1 |
| 10.6 Geron | 69 | 1 |
| 10.7 Advanced Cell Technology | 70 | 1 |
| 10.8 Cytori Therapeutics | 70 | 1 |
| 10.9 Pluristem Therapeutics | 71 | 1 |
| 10.10 Medistem | 71 | 1 |
| 10.11 Neostem | 72 | 1 |
| 11 Stem Cell Research and Development - Conclusion | 73 | 1 |
| 12 Appendix | 74 | 4 |
| 12.1 Market Definitions | 74 | 1 |
| 12.2 Key Support Data | 74 | 1 |
| 12.3 Abbreviations | 74 | 1 |
| 12.4 Methodology | 74 | 3 |
| 12.4.1 Coverage | 75 | 1 |
| 12.4.2 Secondary Research | 75 | 1 |
| 12.4.3 Primary Research | 76 | 1 |
| 12.4.4 Expert Panels | 76 | 1 |
| 12.5 Contact Us | 76 | 1 |
| 12.6 Disclaimer | 76 | 2 |